Chronic Fatigue Syndrome Therapeutics Drug
Chronic Fatigue Syndrome Therapeutics Drug market is segmented by players, region (country), by T ... Read More
Global Neurologic Disorder Treatment Drug Market Research Report 2024
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurologic Disorder Treatment Drug Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Anticholinergic
1.2.3 Antiepileptic
1.2.4 Antipsychotic
1.2.5 Hypnotic and Sedative
1.2.6 Analgesics
1.2.7 Antihypertensive
1.2.8 Anticoagulants
1.2.9 Others
1.3 Market by Application
1.3.1 Global Neurologic Disorder Treatment Drug Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Epilepsy
1.3.3 Alzheimer’s Disease
1.3.4 Parkinson's Disease
1.3.5 Multiple Sclerosis
1.3.6 Cerebrovascular Disease
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neurologic Disorder Treatment Drug Market Perspective (2017-2028)
2.2 Neurologic Disorder Treatment Drug Growth Trends by Region
2.2.1 Neurologic Disorder Treatment Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Neurologic Disorder Treatment Drug Historic Market Size by Region (2017-2022)
2.2.3 Neurologic Disorder Treatment Drug Forecasted Market Size by Region (2023-2028)
2.3 Neurologic Disorder Treatment Drug Market Dynamics
2.3.1 Neurologic Disorder Treatment Drug Industry Trends
2.3.2 Neurologic Disorder Treatment Drug Market Drivers
2.3.3 Neurologic Disorder Treatment Drug Market Challenges
2.3.4 Neurologic Disorder Treatment Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neurologic Disorder Treatment Drug Players by Revenue
3.1.1 Global Top Neurologic Disorder Treatment Drug Players by Revenue (2017-2022)
3.1.2 Global Neurologic Disorder Treatment Drug Revenue Market Share by Players (2017-2022)
3.2 Global Neurologic Disorder Treatment Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Neurologic Disorder Treatment Drug Revenue
3.4 Global Neurologic Disorder Treatment Drug Market Concentration Ratio
3.4.1 Global Neurologic Disorder Treatment Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurologic Disorder Treatment Drug Revenue in 2021
3.5 Neurologic Disorder Treatment Drug Key Players Head office and Area Served
3.6 Key Players Neurologic Disorder Treatment Drug Product Solution and Service
3.7 Date of Enter into Neurologic Disorder Treatment Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neurologic Disorder Treatment Drug Breakdown Data by Type
4.1 Global Neurologic Disorder Treatment Drug Historic Market Size by Type (2017-2022)
4.2 Global Neurologic Disorder Treatment Drug Forecasted Market Size by Type (2023-2028)
5 Neurologic Disorder Treatment Drug Breakdown Data by Application
5.1 Global Neurologic Disorder Treatment Drug Historic Market Size by Application (2017-2022)
5.2 Global Neurologic Disorder Treatment Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Neurologic Disorder Treatment Drug Market Size (2017-2028)
6.2 North America Neurologic Disorder Treatment Drug Market Size by Country (2017-2022)
6.3 North America Neurologic Disorder Treatment Drug Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Neurologic Disorder Treatment Drug Market Size (2017-2028)
7.2 Europe Neurologic Disorder Treatment Drug Market Size by Country (2017-2022)
7.3 Europe Neurologic Disorder Treatment Drug Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neurologic Disorder Treatment Drug Market Size (2017-2028)
8.2 Asia-Pacific Neurologic Disorder Treatment Drug Market Size by Country (2017-2022)
8.3 Asia-Pacific Neurologic Disorder Treatment Drug Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Neurologic Disorder Treatment Drug Market Size (2017-2028)
9.2 Latin America Neurologic Disorder Treatment Drug Market Size by Country (2017-2022)
9.3 Latin America Neurologic Disorder Treatment Drug Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neurologic Disorder Treatment Drug Market Size (2017-2028)
10.2 Middle East & Africa Neurologic Disorder Treatment Drug Market Size by Country (2017-2022)
10.3 Middle East & Africa Neurologic Disorder Treatment Drug Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Neurologic Disorder Treatment Drug Introduction
11.1.4 AbbVie Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.1.5 AbbVie Recent Development
11.2 Acadia Pharmaceuticals
11.2.1 Acadia Pharmaceuticals Company Detail
11.2.2 Acadia Pharmaceuticals Business Overview
11.2.3 Acadia Pharmaceuticals Neurologic Disorder Treatment Drug Introduction
11.2.4 Acadia Pharmaceuticals Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.2.5 Acadia Pharmaceuticals Recent Development
11.3 Acorda Therapeutics Biotechnology
11.3.1 Acorda Therapeutics Biotechnology Company Detail
11.3.2 Acorda Therapeutics Biotechnology Business Overview
11.3.3 Acorda Therapeutics Biotechnology Neurologic Disorder Treatment Drug Introduction
11.3.4 Acorda Therapeutics Biotechnology Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.3.5 Acorda Therapeutics Biotechnology Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Neurologic Disorder Treatment Drug Introduction
11.4.4 Bayer Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.4.5 Bayer Recent Development
11.5 Biogen
11.5.1 Biogen Company Detail
11.5.2 Biogen Business Overview
11.5.3 Biogen Neurologic Disorder Treatment Drug Introduction
11.5.4 Biogen Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.5.5 Biogen Recent Development
11.6 CSK
11.6.1 CSK Company Detail
11.6.2 CSK Business Overview
11.6.3 CSK Neurologic Disorder Treatment Drug Introduction
11.6.4 CSK Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.6.5 CSK Recent Development
11.7 Eisai
11.7.1 Eisai Company Detail
11.7.2 Eisai Business Overview
11.7.3 Eisai Neurologic Disorder Treatment Drug Introduction
11.7.4 Eisai Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.7.5 Eisai Recent Development
11.8 F. Hoffmann La Roche
11.8.1 F. Hoffmann La Roche Company Detail
11.8.2 F. Hoffmann La Roche Business Overview
11.8.3 F. Hoffmann La Roche Neurologic Disorder Treatment Drug Introduction
11.8.4 F. Hoffmann La Roche Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.8.5 F. Hoffmann La Roche Recent Development
11.9 H Lundbeck
11.9.1 H Lundbeck Company Detail
11.9.2 H Lundbeck Business Overview
11.9.3 H Lundbeck Neurologic Disorder Treatment Drug Introduction
11.9.4 H Lundbeck Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.9.5 H Lundbeck Recent Development
11.10 Johnson and Johnson
11.10.1 Johnson and Johnson Company Detail
11.10.2 Johnson and Johnson Business Overview
11.10.3 Johnson and Johnson Neurologic Disorder Treatment Drug Introduction
11.10.4 Johnson and Johnson Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.10.5 Johnson and Johnson Recent Development
11.11 Merck
11.11.1 Merck Company Detail
11.11.2 Merck Business Overview
11.11.3 Merck Neurologic Disorder Treatment Drug Introduction
11.11.4 Merck Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.11.5 Merck Recent Development
11.12 Novartis
11.12.1 Novartis Company Detail
11.12.2 Novartis Business Overview
11.12.3 Novartis Neurologic Disorder Treatment Drug Introduction
11.12.4 Novartis Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.12.5 Novartis Recent Development
11.13 Otsuka Pharmaceutical
11.13.1 Otsuka Pharmaceutical Company Detail
11.13.2 Otsuka Pharmaceutical Business Overview
11.13.3 Otsuka Pharmaceutical Neurologic Disorder Treatment Drug Introduction
11.13.4 Otsuka Pharmaceutical Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.13.5 Otsuka Pharmaceutical Recent Development
11.14 Pfizer
11.14.1 Pfizer Company Detail
11.14.2 Pfizer Business Overview
11.14.3 Pfizer Neurologic Disorder Treatment Drug Introduction
11.14.4 Pfizer Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.14.5 Pfizer Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Detail
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Neurologic Disorder Treatment Drug Introduction
11.15.4 Sanofi Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.15.5 Sanofi Recent Development
11.16 Takeda Pharmaceutical
11.16.1 Takeda Pharmaceutical Company Detail
11.16.2 Takeda Pharmaceutical Business Overview
11.16.3 Takeda Pharmaceutical Neurologic Disorder Treatment Drug Introduction
11.16.4 Takeda Pharmaceutical Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.16.5 Takeda Pharmaceutical Recent Development
11.17 Teva Pharmaceutical Industries
11.17.1 Teva Pharmaceutical Industries Company Detail
11.17.2 Teva Pharmaceutical Industries Business Overview
11.17.3 Teva Pharmaceutical Industries Neurologic Disorder Treatment Drug Introduction
11.17.4 Teva Pharmaceutical Industries Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.17.5 Teva Pharmaceutical Industries Recent Development
11.18 UCB
11.18.1 UCB Company Detail
11.18.2 UCB Business Overview
11.18.3 UCB Neurologic Disorder Treatment Drug Introduction
11.18.4 UCB Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.18.5 UCB Recent Development
11.19 USWM
11.19.1 USWM Company Detail
11.19.2 USWM Business Overview
11.19.3 USWM Neurologic Disorder Treatment Drug Introduction
11.19.4 USWM Revenue in Neurologic Disorder Treatment Drug Business (2017-2022)
11.19.5 USWM Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Neurologic Disorder Treatment Drug Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Anticholinergic
Table 3. Key Players of Antiepileptic
Table 4. Key Players of Antipsychotic
Table 5. Key Players of Hypnotic and Sedative
Table 6. Key Players of Analgesics
Table 7. Key Players of Antihypertensive
Table 8. Key Players of Anticoagulants
Table 9. Key Players of Others
Table 10. Global Neurologic Disorder Treatment Drug Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 11. Global Neurologic Disorder Treatment Drug Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 12. Global Neurologic Disorder Treatment Drug Market Size by Region (2017-2022) & (US$ Million)
Table 13. Global Neurologic Disorder Treatment Drug Market Share by Region (2017-2022)
Table 14. Global Neurologic Disorder Treatment Drug Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 15. Global Neurologic Disorder Treatment Drug Market Share by Region (2023-2028)
Table 16. Neurologic Disorder Treatment Drug Market Trends
Table 17. Neurologic Disorder Treatment Drug Market Drivers
Table 18. Neurologic Disorder Treatment Drug Market Challenges
Table 19. Neurologic Disorder Treatment Drug Market Restraints
Table 20. Global Neurologic Disorder Treatment Drug Revenue by Players (2017-2022) & (US$ Million)
Table 21. Global Neurologic Disorder Treatment Drug Market Share by Players (2017-2022)
Table 22. Global Top Neurologic Disorder Treatment Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurologic Disorder Treatment Drug as of 2021)
Table 23. Ranking of Global Top Neurologic Disorder Treatment Drug Companies by Revenue (US$ Million) in 2021
Table 24. Global 5 Largest Players Market Share by Neurologic Disorder Treatment Drug Revenue (CR5 and HHI) & (2017-2022)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Neurologic Disorder Treatment Drug Product Solution and Service
Table 27. Date of Enter into Neurologic Disorder Treatment Drug Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Neurologic Disorder Treatment Drug Market Size by Type (2017-2022) & (US$ Million)
Table 30. Global Neurologic Disorder Treatment Drug Revenue Market Share by Type (2017-2022)
Table 31. Global Neurologic Disorder Treatment Drug Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 32. Global Neurologic Disorder Treatment Drug Revenue Market Share by Type (2023-2028)
Table 33. Global Neurologic Disorder Treatment Drug Market Size by Application (2017-2022) & (US$ Million)
Table 34. Global Neurologic Disorder Treatment Drug Revenue Market Share by Application (2017-2022)
Table 35. Global Neurologic Disorder Treatment Drug Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 36. Global Neurologic Disorder Treatment Drug Revenue Market Share by Application (2023-2028)
Table 37. North America Neurologic Disorder Treatment Drug Market Size by Country (2017-2022) & (US$ Million)
Table 38. North America Neurologic Disorder Treatment Drug Market Size by Country (2023-2028) & (US$ Million)
Table 39. Europe Neurologic Disorder Treatment Drug Market Size by Country (2017-2022) & (US$ Million)
Table 40. Europe Neurologic Disorder Treatment Drug Market Size by Country (2023-2028) & (US$ Million)
Table 41. Asia-Pacific Neurologic Disorder Treatment Drug Market Size by Region (2017-2022) & (US$ Million)
Table 42. Asia-Pacific Neurologic Disorder Treatment Drug Market Size by Region (2023-2028) & (US$ Million)
Table 43. Latin America Neurologic Disorder Treatment Drug Market Size by Country (2017-2022) & (US$ Million)
Table 44. Latin America Neurologic Disorder Treatment Drug Market Size by Country (2023-2028) & (US$ Million)
Table 45. Middle East & Africa Neurologic Disorder Treatment Drug Market Size by Country (2017-2022) & (US$ Million)
Table 46. Middle East & Africa Neurologic Disorder Treatment Drug Market Size by Country (2023-2028) & (US$ Million)
Table 47. AbbVie Company Detail
Table 48. AbbVie Business Overview
Table 49. AbbVie Neurologic Disorder Treatment Drug Product
Table 50. AbbVie Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 51. AbbVie Recent Development
Table 52. Acadia Pharmaceuticals Company Detail
Table 53. Acadia Pharmaceuticals Business Overview
Table 54. Acadia Pharmaceuticals Neurologic Disorder Treatment Drug Product
Table 55. Acadia Pharmaceuticals Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 56. Acadia Pharmaceuticals Recent Development
Table 57. Acorda Therapeutics Biotechnology Company Detail
Table 58. Acorda Therapeutics Biotechnology Business Overview
Table 59. Acorda Therapeutics Biotechnology Neurologic Disorder Treatment Drug Product
Table 60. Acorda Therapeutics Biotechnology Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 61. Acorda Therapeutics Biotechnology Recent Development
Table 62. Bayer Company Detail
Table 63. Bayer Business Overview
Table 64. Bayer Neurologic Disorder Treatment Drug Product
Table 65. Bayer Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 66. Bayer Recent Development
Table 67. Biogen Company Detail
Table 68. Biogen Business Overview
Table 69. Biogen Neurologic Disorder Treatment Drug Product
Table 70. Biogen Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 71. Biogen Recent Development
Table 72. CSK Company Detail
Table 73. CSK Business Overview
Table 74. CSK Neurologic Disorder Treatment Drug Product
Table 75. CSK Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 76. CSK Recent Development
Table 77. Eisai Company Detail
Table 78. Eisai Business Overview
Table 79. Eisai Neurologic Disorder Treatment Drug Product
Table 80. Eisai Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 81. Eisai Recent Development
Table 82. F. Hoffmann La Roche Company Detail
Table 83. F. Hoffmann La Roche Business Overview
Table 84. F. Hoffmann La Roche Neurologic Disorder Treatment Drug Product
Table 85. F. Hoffmann La Roche Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 86. F. Hoffmann La Roche Recent Development
Table 87. H Lundbeck Company Detail
Table 88. H Lundbeck Business Overview
Table 89. H Lundbeck Neurologic Disorder Treatment Drug Product
Table 90. H Lundbeck Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 91. H Lundbeck Recent Development
Table 92. Johnson and Johnson Company Detail
Table 93. Johnson and Johnson Business Overview
Table 94. Johnson and Johnson Neurologic Disorder Treatment Drug Product
Table 95. Johnson and Johnson Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 96. Johnson and Johnson Recent Development
Table 97. Merck Company Detail
Table 98. Merck Business Overview
Table 99. Merck Neurologic Disorder Treatment DrugProduct
Table 100. Merck Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 101. Merck Recent Development
Table 102. Novartis Company Detail
Table 103. Novartis Business Overview
Table 104. Novartis Neurologic Disorder Treatment DrugProduct
Table 105. Novartis Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 106. Novartis Recent Development
Table 107. Otsuka Pharmaceutical Company Detail
Table 108. Otsuka Pharmaceutical Business Overview
Table 109. Otsuka Pharmaceutical Neurologic Disorder Treatment DrugProduct
Table 110. Otsuka Pharmaceutical Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 111. Otsuka Pharmaceutical Recent Development
Table 112. Pfizer Company Detail
Table 113. Pfizer Business Overview
Table 114. Pfizer Neurologic Disorder Treatment DrugProduct
Table 115. Pfizer Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 116. Pfizer Recent Development
Table 117. Sanofi Company Detail
Table 118. Sanofi Business Overview
Table 119. Sanofi Neurologic Disorder Treatment DrugProduct
Table 120. Sanofi Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 121. Sanofi Recent Development
Table 122. Takeda Pharmaceutical Company Detail
Table 123. Takeda Pharmaceutical Business Overview
Table 124. Takeda Pharmaceutical Neurologic Disorder Treatment DrugProduct
Table 125. Takeda Pharmaceutical Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 126. Takeda Pharmaceutical Recent Development
Table 127. Teva Pharmaceutical Industries Company Detail
Table 128. Teva Pharmaceutical Industries Business Overview
Table 129. Teva Pharmaceutical Industries Neurologic Disorder Treatment DrugProduct
Table 130. Teva Pharmaceutical Industries Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 131. Teva Pharmaceutical Industries Recent Development
Table 132. UCB Company Detail
Table 133. UCB Business Overview
Table 134. UCB Neurologic Disorder Treatment DrugProduct
Table 135. UCB Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 136. UCB Recent Development
Table 137. USWM Company Detail
Table 138. USWM Business Overview
Table 139. USWM Neurologic Disorder Treatment DrugProduct
Table 140. USWM Revenue in Neurologic Disorder Treatment Drug Business (2017-2022) & (US$ Million)
Table 141. USWM Recent Development
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurologic Disorder Treatment Drug Market Share by Type: 2021 VS 2028
Figure 2. Anticholinergic Features
Figure 3. Antiepileptic Features
Figure 4. Antipsychotic Features
Figure 5. Hypnotic and Sedative Features
Figure 6. Analgesics Features
Figure 7. Antihypertensive Features
Figure 8. Anticoagulants Features
Figure 9. Others Features
Figure 10. Global Neurologic Disorder Treatment Drug Market Share by Application in 2021 & 2028
Figure 11. Epilepsy Case Studies
Figure 12. Alzheimer’s Disease Case Studies
Figure 13. Parkinson's Disease Case Studies
Figure 14. Multiple Sclerosis Case Studies
Figure 15. Cerebrovascular Disease Case Studies
Figure 16. Others Case Studies
Figure 17. Neurologic Disorder Treatment Drug Report Years Considered
Figure 18. Global Neurologic Disorder Treatment Drug Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 19. Global Neurologic Disorder Treatment Drug Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 20. Global Neurologic Disorder Treatment Drug Market Share by Region: 2021 VS 2028
Figure 21. Global Neurologic Disorder Treatment Drug Market Share by Players in 2021
Figure 22. Global Top Neurologic Disorder Treatment Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurologic Disorder Treatment Drug as of 2021)
Figure 23. The Top 10 and 5 Players Market Share by Neurologic Disorder Treatment Drug Revenue in 2021
Figure 24. North America Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. North America Neurologic Disorder Treatment Drug Market Share by Country (2017-2028)
Figure 26. United States Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Canada Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Europe Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Europe Neurologic Disorder Treatment Drug Market Share by Country (2017-2028)
Figure 30. Germany Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. France Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. U.K. Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Italy Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Russia Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Nordic Countries Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Asia-Pacific Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Asia-Pacific Neurologic Disorder Treatment Drug Market Share by Region (2017-2028)
Figure 38. China Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Japan Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. South Korea Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Southeast Asia Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. India Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Australia Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Latin America Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Latin America Neurologic Disorder Treatment Drug Market Share by Country (2017-2028)
Figure 46. Mexico Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Brazil Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 48. Middle East & Africa Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Middle East & Africa Neurologic Disorder Treatment Drug Market Share by Country (2017-2028)
Figure 50. Turkey Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 51. Saudi Arabia Neurologic Disorder Treatment Drug Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. AbbVie Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 53. Acadia Pharmaceuticals Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 54. Acorda Therapeutics Biotechnology Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 55. Bayer Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 56. Biogen Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 57. CSK Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 58. Eisai Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 59. F. Hoffmann La Roche Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 60. H Lundbeck Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 61. Johnson and Johnson Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 62. Merck Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 63. Novartis Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 64. Otsuka Pharmaceutical Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 65. Pfizer Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 66. Sanofi Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 67. Takeda Pharmaceutical Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 68. Teva Pharmaceutical Industries Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 69. UCB Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 70. USWM Revenue Growth Rate in Neurologic Disorder Treatment Drug Business (2017-2022)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AbbVie Acadia Pharmaceuticals Acorda Therapeutics Biotechnology Bayer Biogen CSK Eisai F. Hoffmann La Roche H Lundbeck Johnson and Johnson Merck Novartis Otsuka Pharmaceutical Pfizer Sanofi Takeda Pharmaceutical Teva Pharmaceutical Industries UCB USWM